The 2026 state cannabis legislation tracker: eight bills that actually matter

State cannabis legislation does not move at one speed. In any given session, several hundred bills are introduced nationally, a few dozen receive committee hearings, fewer than ten reach a floor vote, and a handful actually become law. The 2026 session has produced unusually high volume (legislative trackers count nearly 500 active cannabis-related bills across the 50 states) but, as in every recent year, the disposition gap between "introduced" and "enacted" remains the operative reality.

This article picks out eight bills that are either consequential because they are moving or instructive because they are not. The selection is biased toward bills that could materially change patient access or adult-use availability if enacted; not the marginal hemp-product or possession-decriminalization adjustments that dominate the raw bill count.

What "moving" means in 2026

Before the bill-by-bill: a piece of background. The 2026 federal Schedule III order (issued April 22, 2026) has not produced a corresponding rush of state legislation. Most state legislatures had already adjourned or were past the bill-introduction deadline by the time the DOJ acted, and state-level adult-use and medical statutes operate largely independent of federal scheduling. What state legislators are responding to in 2026 is a combination of (a) ongoing pressure from neighboring legalized states' tax revenue, (b) hemp-derived-cannabinoid regulation, and (c) the steady expansion of medical-program qualifying conditions.

1. Virginia — HB 642 / SB 542 (adult-use retail sales)

Status: passed both chambers, awaiting gubernatorial action (deadline May 22, 2026).

Virginia legalized adult-use possession in 2021 but never authorized a retail market. The 2026 General Assembly passed companion bills (HB 642 / SB 542) authorizing retail sales beginning January 1, 2027. On April 13, 2026, Governor Spanberger returned the bills to the legislature with a substitute containing significant amendments. Under Virginia's process, the governor has until May 22, 2026 to sign as-passed, veto, or allow to become law without signature.

The substantive question turns on whether Spanberger's amendments are accepted by the legislature in a special session, or whether the legislature insists on the original bill text and the governor vetoes. Either outcome is structurally consistent with the five-year stalemate that has defined Virginia adult-use retail since 2021.

2. Pennsylvania — SB 120 (adult-use legalization)

Status: passed Senate Law and Justice Committee October 2025; awaiting full Senate vote.

SB 120, the bipartisan Laughlin/Street bill, is the furthest any Pennsylvania adult-use bill has advanced. The bill would legalize possession of 30 grams of flower, 5 grams of concentrate, or 1,000 mg of infused THC for adults 21+; tax sales at 14%; and establish a new Cannabis Control Board to license private operators within six months of enactment.

The structural obstacle is Senate Majority Leader Joe Pittman (R), who has publicly stated he does not see prevailing support for adult-use within the Republican caucus. The House companion (HB 20) has received no hearing. Practical reading: SB 120 could clear the Senate but faces a hostile House posture, and there is no realistic path to law before the 2026 session adjourns.

3. North Carolina — H 413 (adult-use) and SB 1072 (ballot amendment)

Status: H 413 in House Rules Committee, no hearing; SB 1072 filed May 2026.

North Carolina remains one of the largest US states without any medical-cannabis program. H 413 (2025) would legalize adult-use for 21+. It is sponsored by Democratic legislators in a Republican-supermajority legislature and has not received a hearing. The Compassionate Care Act (H 1011, the medical-cannabis vehicle) is in the same posture.

The more interesting vehicle is SB 1072 (filed May 2026 by Sens. Smith, Theodros, and Lowe), which would place two cannabis-related constitutional amendments on the November 2026 ballot: one decriminalizing possession, one establishing a constitutional right to medical-cannabis access for patients with qualifying conditions. Constitutional amendments in North Carolina require three-fifths legislative approval to reach the ballot — a high bar in the current chamber composition. The bill's symbolic value (and the polling data it will generate) may exceed its near-term legislative prospects.

4. Hawaii — SB 3275 (low-dose adult-use)

Status: passed Senate Health and Human Services Committee February 2026; broader SB 1613 stalled.

After multiple failed attempts to pass broad adult-use legalization, Hawaii's 2026 session has settled on a narrower vehicle: SB 3275 would legalize low-dose, low-potency cannabis (≤ 5 mg THC per serving) for personal use by adults 21+ starting January 1, 2027. The bill does not establish a commercial licensing regime; possession and personal use would be legal but no licensed adult-use retail would exist.

The legislative logic: pass a politically defensible reform that locks in possession decriminalization while deferring the commercial regulation fight to a future session. The House signaled in early 2026 that broad legalization (SB 1613) was dead for the year. SB 3275 represents Hawaii's most plausible 2026 adult-use enactment.

5. Kentucky — Senate Bill 47 implementation cycle

Status: enacted (2023); medical program operational January 2026.

Kentucky's medical-cannabis statute is law, but 2026 is the first year of operational implementation. The 2026 session has produced multiple implementation-cycle bills addressing dispensary licensing pace, qualifying-condition additions, employment protections, and patient-registration friction. None of these is individually decisive, but the cumulative effect of the 2026 implementation bills will shape whether Kentucky's program scales to a comparable adoption curve to its eastern neighbors. For program-specific operational detail see the companion article on Kentucky's 2026 launch.

6. New Hampshire — HB 186 / CACR 19

Status: HB 186 passed House (208-135), tabled by Senate; CACR 19 constitutional amendment introduced.

The 2026 New Hampshire session repeated the 2024 pattern: House passes legalization, Senate kills it. Governor Kelly Ayotte (R) campaigned on opposition to legalization, making any bill reaching her desk a near-certain veto. The constitutional-amendment vehicle (CACR 19) sponsored by Rep. Wheeler does not require gubernatorial action but requires a three-fifths legislative supermajority that the chamber composition does not support.

The structural reading: New Hampshire is procedurally locked. The House supports legalization, the Senate and governor do not, and the constitutional-amendment workaround does not have the supermajority math. Patients should expect a multi-session timeline.

7. Tennessee — SB 809 / SB 923 / HB 981 (all dead)

Status: failed in committee, 2026 session.

Tennessee remains one of the most restrictive cannabis-policy states. The 2026 session saw three legalization bills (SB 809, SB 923, HB 981) and all three died in committee without hearings. Tennessee operates a limited low-THC oil program for select conditions; no comprehensive medical or adult-use bill has advanced past committee in any recent session. The 2026 outcome continues an unbroken pattern.

8. Texas — HB 46 implementation aftermath

Status: enacted (June 2025); DPS licensing rollout in progress through April 2026.

HB 46 (2025) is the law of Texas as of June 21, 2025. The 2026 legislative session did not produce another expansion bill. What is "moving" in Texas in 2026 is the regulatory implementation: the Department of Public Safety has issued conditional licenses through December 2025 (9 licenses) and through April 2026 (3 additional licenses), bringing the total Compassionate Use Program operator count toward the statutory 15. For the operational detail on TCUP enrollment trends see the companion article on Texas's HB 46 impact.

Honorable mentions: bills worth tracking but not yet decisive

Beyond the eight above, several 2026 bills are worth watching even though their near-term legislative prospects are limited:

• Florida SB 1398 (adult-use legalization, no committee hearing) — the only adult-use bill in the 2026 Florida session. Failed to advance. The companion patient-protection bills (S 0776 cultivation rights, S 0130 / H 1061 child-endangerment protections, S 0136 / H 0689 employment protections) suffered the same disposition.
• Mississippi HB 611 / SB 2748 — potency-cap adjustment and "right to try" provisions for the existing Medical Cannabis Program. Mixed committee results; covered in the Mississippi MMCP article.
• Washington state cannabis omnibus — multiple regulatory-adjustment bills moving through both chambers, focused on retail-licensing and labor-standard updates rather than scope expansion.
• Multi-state hemp policy — Georgia, Indiana, Kentucky, Minnesota, Missouri, Virginia, and Washington have all produced 2026 hemp-product regulation bills, several of which address THCA and hemp-derived-Delta-9 sales channels that have functioned as de facto adult-use substitutes since 2019.
• California labor-rights legislation — several bills addressing cannabis-workforce employment protections and worker-classification rules, building on the state's existing comprehensive medical and adult-use frameworks.

These bills will not flip a state from prohibition to legalization. They will adjust the operating parameters of existing programs, sometimes meaningfully.

What 2026 will not produce

A useful exercise: identifying the bills that 2026 will not deliver, despite headline-level expectation.

• No new adult-use legalization states. Virginia is the closest to a positive outcome, and Virginia's case is sales authorization rather than legalization (adult-use possession has been legal since 2021). Pennsylvania, Hawaii, and the various Northeast states are not on a 2026 enactment path.
• No new comprehensive medical states. Kentucky launched in January 2026 under prior legislation. No 2026 session is set to add a new state to the medical-cannabis roster.
• No federal-level state-program preemption. The April 2026 DOJ rescheduling did not modify state-program authority. Congress has not advanced banking, descheduling, or interstate-commerce legislation.
• No ballot-question resolution in the major contested states. Florida's 2026 effort collapsed at signature validation. Other states' 2026 ballot prospects (North Carolina, Nebraska potentially) are not certified for the November 2026 ballot as of this writing.

The 2026 cannabis legislative year is largely a year of holding patterns: existing programs implementing, new programs operationalizing, contested programs failing in committee, and the federal layer above producing one limited Schedule III move that did not translate into state-level momentum.

Patterns visible in the 2026 docket

Three patterns emerge across these eight bills:

The Republican-supermajority states are still locked. Tennessee, North Carolina, South Carolina, Alabama, Indiana, and Wisconsin produced no advancing bills. The Republican-supermajority legislative composition is the operative variable, and the federal Schedule III order has not shifted it.

The split-control states are stuck in iteration. Virginia, New Hampshire, and (to a lesser extent) Pennsylvania have functioning legalization coalitions in one chamber but not the other. The bills clear one body and die in the other or arrive on a hostile governor's desk. The cycle repeats.

The medical-expansion states are moving incrementally. Texas (HB 46), Kentucky (SB 47 implementation), and the multi-state hemp-policy bills are doing the actual work of expanding patient access in 2026, while the adult-use headlines remain mostly aspirational. Patients tracking access changes should pay more attention to medical-condition additions and dispensary-licensing pace than to the much-publicized adult-use floor votes.

What to watch through fall 2026

The May 22 Spanberger decision in Virginia is the most consequential near-term event. After that, the question is whether SB 120 reaches the Pennsylvania Senate floor (a vote could come in June or be deferred to fall), whether SB 3275 clears the Hawaii House before adjournment, and whether the Texas DPS finalizes its remaining TCUP license issuances on the April 2026 schedule.

For the federal angle, the June 29, 2026 DEA ALJ hearing on broader marijuana rescheduling will produce a procedural record that may (or may not) influence state legislative calculations for the 2027 session. State legislators do not typically vote on federal scheduling, but federal scheduling shifts the political topology within which state cannabis policy is debated.

[Last reviewed 2026-05-18. This is informational only — not medical or legal advice.]